Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
MWN-AI** Summary
Verrica Pharmaceuticals Inc., a Pennsylvania-based company specializing in dermatology therapeutics, has appointed Chris Chapman as its new Chief Commercial Officer, effective immediately. Jayson Rieger, President and CEO of Verrica, expressed confidence in Chapman's extensive background and commercial expertise, particularly in dermatology, to enhance the reach of their lead product, YCANTH (VP-102), which treats molluscum contagiosum. YCANTH is notable as the first FDA-approved healthcare professional-administered treatment for this contagious skin condition, affecting roughly 6 million individuals, primarily children, in the U.S.
Chapman, who has over 25 years of commercial experience in the pharmaceutical sector, previously served as Chief Commercial Officer at Dermavant Sciences. His strategic leadership was pivotal during the launch of VTAMA, a treatment for adult plaque psoriasis and atopic dermatitis. Additionally, he played a significant role in integrating Dermavant into Organon following its acquisition.
In his new role at Verrica, Chapman is excited about the potential of YCANTH to establish new standards for molluscum treatment and is also looking forward to advancing the global development of the company’s pipeline candidate, VP-315, a novel oncolytic peptide aimed at treating basal cell carcinoma. He emphasizes the opportunity to develop a U.S. commercial strategy that aligns with Verrica's broader expansion objectives.
Verrica is dedicated to addressing unmet needs in dermatological treatments, and under Chapman’s leadership, the company aspires to enhance accessibility to their innovative therapies while continuing to explore avenues for new product developments. With his considerable experience in launching and managing commercial operations in competitive markets, Chapman is poised to contribute significantly to Verrica's strategic growth and patient access initiatives.
MWN-AI** Analysis
The recent appointment of Chris Chapman as Chief Commercial Officer at Verrica Pharmaceuticals signifies an important strategic move for the company and may provide promising opportunities for investors. With over 25 years of experience, including key roles at Dermavant and Galderma, Chapman's expertise in dermatology commercialization is poised to enhance Verrica's market reach, particularly for its flagship product, YCANTH (VP-102), which is FDA-approved for treating molluscum contagiosum in patients aged two and older.
Verrica’s YCANTH offers a unique value proposition in a market with limited approved therapies for molluscum and has significant growth potential as it expands into common warts, which impacts millions without FDA-approved options. This creates a ripe environment for revenue generation, especially as the U.S. market has approximately 250 million lives potentially covered for YCANTH, allowing for broader access and affordability, with just a $25 co-pay for commercially insured patients.
Moreover, Chapman’s experience, particularly his role in successfully launching products in competitive markets, could be pivotal in executing effective commercialization strategies for not only YCANTH but also for Verrica's developmental pipeline, including VP-315, targeted at basal cell carcinoma.
Given the current trajectory of market engagement and product development, investors should closely monitor Verrica's performance metrics and progress reports following this appointment. The dermatology therapeutics sector is highly dynamic, and with increased commercialization efforts, Verrica may present a compelling investment opportunity as it seeks to capitalize on unmet medical needs within dermatological care. However, potential investors should remain vigilant of inherent risks tied to market acceptance and competitive dynamics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer.
“It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. “Chris has an extraordinary track record of successfully commercializing several products in dermatology and other specialties, and has had success in building and leading commercial organizations in dynamic and competitive markets. I am confident that Chris’ commercial acumen will broaden access to YCANTH for molluscum patients and bring critical insights to our global Phase 3 program for common warts as well as the development of VP-315, our novel oncolytic peptide for basal cell carcinoma.”
“I am excited to join Verrica at a time when YCANTH is becoming the new standard of care for the millions of children impacted by molluscum contagiosum,” said Mr. Chapman. “YCANTH represents a rare product opportunity based not only on its growth potential in molluscum, but also as a potential future treatment for common warts, an indication impacting millions of additional patients for which there are no FDA-approved therapies. I am also excited by the opportunity for Verrica’s other pipeline candidate, VP-315, which has the potential to become a best-in-class non-surgical immunotherapeutic option for the treatment of basal cell carcinoma. I relish the opportunity to lead and grow the U.S. commercial organization, while supporting Verrica’s global expansion goals for YCANTH.”
Mr. Chapman brings over 25 years of commercial experience in the pharmaceutical industry to Verrica. Most recently, he served as Chief Commercial Officer at Dermavant Sciences, where he played an instrumental role in launching VTAMA® (tapinarof) cream, 1%, approved for adult plaque psoriasis in June 2022 and atopic dermatitis in December 2024. He was also a key leader in integrating the Dermavant commercial organization with Organon after its acquisition of Dermavant in October 2024.
Prior to his roles with Dermavant and Organon, Mr. Chapman served as Vice President & General Manager, U.S. Prescription Business for Galderma, where he led the U.S. Prescription Business. Prior to Galderma, Chris spent 20 years in commercial roles at Pfizer, where he led the U.S. Pharmaceutical Contracting and Pricing Organization.
Mr. Chapman received a Bachelor of Science degree from Towson University.
About YCANTH® (VP-102)
YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH was a safe and effective therapeutic for the treatment of molluscum. Approximately 250 million lives are eligible to receive YCANTH covered by insurance. Commercially insured patients pay just $25 per YCANTH treatment visit, for up to two applicators. Other uninsured patients may be eligible to receive YCANTH at a reduced cost if certain eligibility requirements are met for patient assistance. Please visit YCANTHPro.com for additional information.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the commercialization of YCANTH, including broadened access for molluscum patients, and the clinical development and benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2024, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ**
How will the appointment of Chris Chapman as Chief Commercial Officer impact the growth strategy for Verrica Pharmaceuticals Inc. (VRCA) in expanding YCANTH’s market access for treating molluscum contagiosum?
What specific commercial insights does Chris Chapman bring to Verrica Pharmaceuticals Inc. (VRCA) that could enhance the success of VP-315 in the treatment of basal cell carcinoma?
With the FDA approval of YCANTH by Verrica Pharmaceuticals Inc. (VRCA), what measures are being taken to ensure that commercially insured patients can afford their treatment with just a $25 copay?
What are the potential risks outlined by Verrica Pharmaceuticals Inc. (VRCA) regarding the commercialization of YCANTH and the clinical development timelines for its product candidates?
**MWN-AI FAQ is based on asking OpenAI questions about Verrica Pharmaceuticals Inc. (NASDAQ: VRCA).
NASDAQ: VRCA
VRCA Trading
1.85% G/L:
$5.22 Last:
25,594 Volume:
$5.10 Open:
